raloxifene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antiestrogens or estrogen receptor modulators, clomifene and tamoxifen derivatives	2351	84449-90-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: raloxifene keoxifene raloxifene hydrochloride evista raloxifene HCl	A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. Molecular weight: 473.59 Formula: C28H27NO4S CLOGP: 6.86 LIPINSKI: 1 HAC: 5 HDO: 2 TPSA: 70 ALOGS: -5.97 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

raloxifene
keoxifene
raloxifene hydrochloride
evista
raloxifene HCl

A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Molecular weight: 473.59
Formula: C28H27NO4S
CLOGP: 6.86
LIPINSKI: 1
HAC: 5
HDO: 2
TPSA: 70
ALOGS: -5.97
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
60	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.01 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	21.12 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	2 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	7.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	10.80 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.05 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	12.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 9, 1997	FDA	LILLY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Endometrial cancer	249.05	12.10	77	19832	2806	50582409
Breast cancer	221.82	12.10	162	19747	42728	50542487
Deep vein thrombosis	157.38	12.10	168	19741	73136	50512079
Retinal vein thrombosis	143.84	12.10	33	19876	364	50584851
Bone density decreased	142.91	12.10	75	19834	11000	50574215
Pulmonary embolism	122.22	12.10	174	19735	101530	50483685
Fracture	104.15	12.10	71	19838	16762	50568453
Spinal compression fracture	99.42	12.10	62	19847	12594	50572621
Femur fracture	98.80	12.10	96	19813	37368	50547847
Retinal vein occlusion	81.83	12.10	30	19879	1851	50583364
Breast cancer female	81.55	12.10	44	19865	6818	50578397
Hip fracture	77.04	12.10	71	19838	25860	50559355
Transient ischaemic attack	69.35	12.10	74	19835	32136	50553079
Body height decreased	65.85	12.10	42	19867	8866	50576349
Thoracic vertebral fracture	65.44	12.10	32	19877	4041	50581174
Cerebral infarction	63.88	12.10	59	19850	21545	50563670
Compression fracture	62.66	12.10	35	19874	5802	50579413
Breast cancer in situ	59.22	12.10	22	19887	1409	50583806
Lumbar vertebral fracture	58.92	12.10	31	19878	4566	50580649
Fall	58.87	12.10	274	19635	334658	50250557
Pelvic fracture	58.32	12.10	43	19866	11477	50573738
Drug ineffective	57.58	12.10	151	19758	819182	49766033
Oestrogen receptor assay positive	56.50	12.10	16	19893	427	50584788
Spinal fracture	54.93	12.10	47	19862	15526	50569689
Toxicity to various agents	52.50	12.10	10	19899	212489	50372726
Cerebrovascular accident	52.04	12.10	115	19794	94565	50490650
Visual acuity reduced	48.25	12.10	49	19860	20090	50565125
Osteonecrosis of jaw	45.56	12.10	60	19849	32466	50552749
Low turnover osteopathy	43.01	12.10	24	19885	3970	50581245
Ovarian cancer	42.40	12.10	26	19883	5123	50580092
Endometrial cancer stage I	42.04	12.10	11	19898	216	50584999
Product use issue	41.56	12.10	5	19904	149470	50435745
Muscle spasms	41.53	12.10	126	19783	125427	50459788
Wrist fracture	41.19	12.10	35	19874	11452	50573763
Off label use	40.02	12.10	79	19830	474347	50110868
Infusion related reaction	39.76	12.10	9	19900	169548	50415667
Postmenopausal haemorrhage	39.31	12.10	18	19891	1962	50583253
Osteonecrosis	38.67	12.10	46	19863	22471	50562744
Hot flush	38.19	12.10	65	19844	44104	50541111
Retinal vascular thrombosis	35.40	12.10	9	19900	157	50585058
Product complaint	35.23	12.10	32	19877	11434	50573781
Blindness unilateral	34.57	12.10	23	19886	5212	50580003
Systemic lupus erythematosus	33.91	12.10	7	19902	140615	50444600
Uterine cancer	33.28	12.10	20	19889	3800	50581415
Synovitis	32.40	12.10	5	19904	123860	50461355
Rheumatoid arthritis	32.13	12.10	20	19889	202530	50382685
Myocardial infarction	31.95	12.10	92	19817	88935	50496280
Uterine polyp	31.77	12.10	15	19894	1753	50583462
Treatment failure	30.90	12.10	8	19901	137629	50447586
Drug intolerance	30.35	12.10	25	19884	219079	50366136
Glossodynia	29.47	12.10	5	19904	115564	50469651
Cataract	28.90	12.10	60	19849	47240	50537975
Endometrial cancer stage II	28.72	12.10	5	19904	10	50585205
Multiple fractures	27.58	12.10	22	19887	6589	50578626
Stress fracture	26.83	12.10	22	19887	6853	50578362
Hyperlipidaemia	25.63	12.10	33	19876	17457	50567758
Intestinal pseudo-obstruction	25.48	12.10	10	19899	744	50584471
Oedema peripheral	25.31	12.10	126	19783	157835	50427380
Retinal haemorrhage	25.23	12.10	18	19891	4563	50580652
Rib fracture	24.69	12.10	34	19875	19187	50566028
Therapeutic product effect decreased	23.63	12.10	12	19897	136038	50449177
Therapeutic product effect incomplete	23.24	12.10	4	19905	91511	50493704
Alopecia	23.12	12.10	38	19871	245009	50340206
Embolism	22.50	12.10	20	19889	6948	50578267
Lower respiratory tract infection	22.41	12.10	5	19904	95196	50490019
Lumbar spinal stenosis	22.14	12.10	16	19893	4138	50581077
Injection site haemorrhage	21.96	12.10	34	19875	21312	50563903
Embolism venous	21.43	12.10	13	19896	2512	50582703
Femoral neck fracture	21.26	12.10	20	19889	7470	50577745
Breast cancer recurrent	21.06	12.10	15	19894	3793	50581422
Oestrogen receptor assay negative	20.52	12.10	3	19906	0	50585215
Peripheral swelling	20.30	12.10	31	19878	205905	50379310
Ischaemic stroke	20.17	12.10	28	19881	15920	50569295
Joint swelling	19.64	12.10	42	19867	245244	50339971
Dementia Alzheimer's type	19.28	12.10	9	19900	1025	50584190
Fibrocystic breast disease	18.87	12.10	9	19900	1075	50584140
Intramedullary rod insertion	18.80	12.10	11	19898	1989	50583226
Pericarditis	18.79	12.10	4	19905	78685	50506530
Endometrial hyperplasia	18.78	12.10	8	19901	734	50584481
Osteopenia	18.77	12.10	28	19881	16990	50568225
Diverticulum	18.74	12.10	22	19887	10592	50574623
Back pain	18.58	12.10	149	19760	219881	50365334
Uterine leiomyoma	18.53	12.10	19	19890	7872	50577343
Thrombosis	18.40	12.10	56	19853	55777	50529438
Spinal osteoarthritis	18.21	12.10	25	19884	14067	50571148
Intentional product use issue	18.18	12.10	4	19905	76914	50508301
Swelling	18.15	12.10	32	19877	200840	50384375
Bone pain	18.10	12.10	50	19859	47179	50538036
Pain	17.46	12.10	145	19764	578758	50006457
Humerus fracture	17.27	12.10	18	19891	7600	50577615
General physical health deterioration	16.52	12.10	19	19890	142415	50442800
Infection	16.13	12.10	27	19882	172927	50412288
Breast swelling	15.86	12.10	8	19901	1079	50584136
Colitis ischaemic	15.67	12.10	19	19890	9464	50575751
Insulinoma	15.46	12.10	4	19905	75	50585140
Foot fracture	15.33	12.10	28	19881	20063	50565152
Blood calcium increased	15.32	12.10	17	19892	7702	50577513
Colon cancer	15.32	12.10	18	19891	8673	50576542
Feeling abnormal	15.31	12.10	93	19816	125399	50459816
Hepatic enzyme increased	15.22	12.10	19	19890	137361	50447854
Gastrooesophageal reflux disease	15.21	12.10	65	19844	76363	50508852
Lung neoplasm malignant	15.01	12.10	24	19885	15460	50569755
Kyphosis	14.95	12.10	10	19899	2285	50582930
Thrombotic stroke	14.80	12.10	6	19903	486	50584729
Wound	14.72	12.10	12	19897	105782	50479433
Fractured sacrum	14.60	12.10	9	19900	1789	50583426
Drug abuse	14.37	12.10	3	19906	59843	50525372
Pleurisy	14.30	12.10	16	19893	7315	50577900
Endometrial hypertrophy	14.22	12.10	5	19904	273	50584942
Coronary artery disease	13.99	12.10	34	19875	29692	50555523
Breast cancer stage III	13.94	12.10	11	19898	3245	50581970
Product use in unapproved indication	13.92	12.10	15	19894	115804	50469411
Intervertebral disc protrusion	13.80	12.10	27	19882	20366	50564849
Jaw disorder	13.65	12.10	13	19896	4930	50580285
Subacute hepatic failure	13.61	12.10	4	19905	122	50585093
Haemorrhage subcutaneous	13.48	12.10	10	19899	2691	50582524
Gastrointestinal tract adenoma	13.45	12.10	5	19904	321	50584894
Intentional overdose	13.34	12.10	4	19905	62500	50522715
Osteomyelitis	13.23	12.10	28	19881	22325	50562890
Sarcoma uterus	13.17	12.10	3	19906	32	50585183
Erythema multiforme	13.14	12.10	17	19892	9033	50576182
Atrophic vulvovaginitis	12.99	12.10	8	19901	1588	50583627
Fracture nonunion	12.93	12.10	9	19900	2195	50583020
Bone disorder	12.90	12.10	25	19884	18727	50566488
Tibia fracture	12.80	12.10	12	19897	4463	50580752
Vision blurred	12.76	12.10	63	19846	78584	50506631
Road traffic accident	12.71	12.10	29	19880	24323	50560892
Breast calcifications	12.60	12.10	7	19902	1148	50584067
Ligament sprain	12.60	12.10	18	19891	10507	50574708
Fatigue	12.40	12.10	200	19709	707401	49877814
Glaucoma	12.14	12.10	22	19887	15664	50569551
Osteoporotic fracture	12.14	12.10	10	19899	3135	50582080

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Endometrial cancer	156.48	12.66	43	14153	1867	64482669
Bone density decreased	131.06	12.66	57	14139	9895	64474641
Breast cancer	108.66	12.66	72	14124	29076	64455460
Retinal vein thrombosis	104.91	12.66	25	14171	608	64483928
Deep vein thrombosis	97.65	12.66	118	14078	105064	64379472
Spinal compression fracture	95.48	12.66	52	14144	14723	64469813
Breast cancer female	83.11	12.66	34	14162	5069	64479467
Thoracic vertebral fracture	79.87	12.66	32	14164	4521	64480015
Femur fracture	76.47	12.66	62	14134	34073	64450463
Oestrogen receptor assay positive	72.68	12.66	16	14180	270	64484266
Pulmonary embolism	71.63	12.66	121	14075	146235	64338301
Body height decreased	67.31	12.66	33	14163	7521	64477015
Fracture	64.31	12.66	44	14152	18711	64465825
Hip fracture	58.13	12.66	48	14148	27051	64457485
Lumbar vertebral fracture	58.05	12.66	27	14169	5475	64479061
Transient ischaemic attack	53.60	12.66	57	14139	44125	64440411
Retinal vein occlusion	52.41	12.66	21	14175	2967	64481569
Endometrial cancer stage I	52.23	12.66	11	14185	149	64484387
Toxicity to various agents	51.52	12.66	9	14187	363504	64121032
Spinal fracture	50.61	12.66	35	14161	15139	64469397
Wrist fracture	48.00	12.66	29	14167	9972	64474564
Compression fracture	47.90	12.66	24	14172	5728	64478808
Pelvic fracture	46.54	12.66	29	14167	10534	64474002
Fall	42.64	12.66	193	14003	416633	64067903
Breast cancer in situ	42.00	12.66	13	14183	859	64483677
Product complaint	40.87	12.66	28	14168	11926	64472610
Postmenopausal haemorrhage	39.41	12.66	14	14182	1421	64483115
Visual acuity reduced	38.32	12.66	38	14158	27103	64457433
Cerebrovascular accident	37.35	12.66	89	14107	137494	64347042
Muscle spasms	36.97	12.66	90	14106	140933	64343603
Hot flush	36.68	12.66	48	14148	46187	64438349
Multiple fractures	35.56	12.66	20	14176	6020	64478516
Endometrial cancer stage II	34.17	12.66	5	14191	4	64484532
Ovarian cancer	34.12	12.66	16	14180	3303	64481233
Off label use	33.43	12.66	55	14141	632751	63851785
Uterine polyp	32.93	12.66	12	14184	1310	64483226
Osteonecrosis of jaw	31.06	12.66	41	14155	39784	64444752
Injection site haemorrhage	30.64	12.66	32	14164	24246	64460290
Uterine cancer	29.89	12.66	14	14182	2884	64481652
Completed suicide	26.89	12.66	8	14188	224406	64260130
Osteonecrosis	26.69	12.66	32	14164	28197	64456339
Bone pain	25.47	12.66	41	14155	47531	64437005
Death	24.49	12.66	43	14153	482662	64001874
Drug ineffective	23.09	12.66	101	14095	840146	63644390
Oedema peripheral	22.65	12.66	99	14097	210218	64274318
Cerebral infarction	21.46	12.66	35	14161	41009	64443527
Blindness unilateral	21.15	12.66	15	14181	6746	64477790
Feeling abnormal	21.05	12.66	71	14125	133531	64351005
Cataract	20.68	12.66	39	14157	51223	64433313
Hyperlipidaemia	20.02	12.66	25	14171	22951	64461585
Low turnover osteopathy	19.17	12.66	9	14187	1864	64482672
Product use issue	18.93	12.66	5	14191	151710	64332826
Intestinal pseudo-obstruction	18.60	12.66	9	14187	1991	64482545
Ischaemic stroke	18.31	12.66	27	14169	29008	64455528
Endometrial hyperplasia	18.06	12.66	6	14190	498	64484038
Blood calcium increased	18.04	12.66	15	14181	8527	64476009
Intervertebral disc degeneration	17.83	12.66	18	14178	13102	64471434
Acute kidney injury	17.78	12.66	46	14150	449194	64035342
Diverticulum	17.75	12.66	18	14178	13180	64471356
Infusion related reaction	17.73	12.66	7	14189	164460	64320076
Myocardial infarction	17.04	12.66	77	14119	165744	64318792
Uterine leiomyoma	17.00	12.66	12	14184	5357	64479179
Insulinoma	16.87	12.66	4	14192	95	64484441
Back pain	16.65	12.66	103	14093	250068	64234468
Stress fracture	16.50	12.66	12	14184	5612	64478924
Foot fracture	16.21	12.66	20	14176	18137	64466399
Atrophic vulvovaginitis	16.20	12.66	7	14189	1194	64483342
Femoral neck fracture	15.74	12.66	14	14182	8710	64475826
Retinal haemorrhage	15.64	12.66	13	14183	7385	64477151
Injection site erythema	15.25	12.66	42	14154	70758	64413778
Osteomyelitis	15.07	12.66	24	14172	27563	64456973
Fractured sacrum	14.82	12.66	7	14189	1468	64483068
Endometrial hypertrophy	14.75	12.66	4	14192	165	64484371
Neutropenia	14.38	12.66	19	14177	239605	64244931
Dementia Alzheimer's type	14.10	12.66	6	14190	986	64483550
Osteoarthritis	14.07	12.66	38	14158	63298	64421238
Vascular headache	13.96	12.66	3	14193	45	64484491
Jaw disorder	13.88	12.66	10	14186	4607	64479929
Gastrooesophageal reflux disease	13.82	12.66	45	14151	83098	64401438
Breast swelling	13.78	12.66	6	14190	1042	64483494
Breast cancer recurrent	13.72	12.66	8	14188	2575	64481961
Osteoporotic fracture	13.67	12.66	9	14187	3589	64480947
Tibia fracture	13.64	12.66	10	14186	4735	64479801
Benign vulval neoplasm	13.55	12.66	3	14193	52	64484484
General physical health deterioration	13.55	12.66	15	14181	204410	64280126
Erythema multiforme	13.55	12.66	17	14179	15684	64468852
Multiple organ dysfunction syndrome	13.31	12.66	3	14193	101410	64383126
Fibrocystic breast disease	13.29	12.66	5	14191	597	64483939
Rib fracture	13.25	12.66	21	14175	24017	64460519
Bone disorder	12.67	12.66	17	14179	16742	64467794

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G03XC01	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Selective estrogen receptor modulators
FDA MoA	N0000000168	Selective Estrogen Receptor Modulators
CHEBI has role	CHEBI:50646	antiosteoporotic
CHEBI has role	CHEBI:50837	oestrogen antagonist
FDA EPC	N0000175826	Estrogen Agonist/Antagonist
MeSH PA	D050071	Bone Density Conservation Agents
MeSH PA	D004965	Estrogen Antagonists
MeSH PA	D020847	Estrogen Receptor Modulators
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D020845	Selective Estrogen Receptor Modulators

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Postmenopausal osteoporosis	indication	102447009
Prevention of Breast Carcinoma	indication
Prevention of Glucocorticoid-Induced Osteoporosis	off-label use
Lupus anticoagulant disorder	contraindication	19267009
Hypertensive disorder	contraindication	38341003	DOID:10763
Thrombosis of retinal vein	contraindication	46085004
Chronic heart failure	contraindication	48447003
Atrial fibrillation	contraindication	49436004	DOID:0060224
Thrombophlebitis	contraindication	64156001	DOID:3875
Deep venous thrombosis	contraindication	128053003
Impaired renal function disorder	contraindication	197663003
Cerebrovascular accident	contraindication	230690007
Pulmonary thromboembolism	contraindication	233935004
Thrombophilia	contraindication	234467004	DOID:2452
Disease of liver	contraindication	235856003	DOID:409
Transient ischemic attack	contraindication	266257000	DOID:224
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Cardiovascular event risk	contraindication	395112001
Breastfeeding (mother)	contraindication	413712001
Disorder of coronary artery	contraindication	414024009
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.13	acidic
pKa2	8.6	acidic
pKa3	9.15	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Estrogen receptor	Nuclear hormone receptor	P03372	ESR1_HUMAN	ANTAGONIST	IC50	9.40	WOMBAT-PK	IUPHAR
Estrogen receptor beta	Nuclear hormone receptor	Q92731	ESR2_HUMAN	MODULATOR	EC50	8	WOMBAT-PK	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	6.41	DRUG MATRIX
Adenosine receptor A2a	GPCR	P29274	AA2AR_HUMAN		Ki	5.93	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.21	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.42	CHEMBL
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Enzyme	Q15125	EBP_HUMAN		Ki	9	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.72	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6.55	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.38	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.16	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.21	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.30	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.77	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.28	DRUG MATRIX
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	8.54	WOMBAT-PK
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	6.52	WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.97	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.83	DRUG MATRIX
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN		EC50	4.93	CHEMBL
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	6.32	DRUG MATRIX
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	6.19	DRUG MATRIX
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	5.63	DRUG MATRIX
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN		IC50	6.40	DRUG MATRIX
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	5.70	DRUG MATRIX
G-protein coupled estrogen receptor 1	GPCR	Q99527	GPER1_HUMAN		EC50	6.50	WOMBAT-PK
Interleukin-6	Cytokine	P05231	IL6_HUMAN		IC50	8.05	WOMBAT-PK
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.44	DRUG MATRIX
Bile acid receptor	Nuclear hormone receptor	Q96RI1	NR1H4_HUMAN		IC50	4.94	CHEMBL
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.88	DRUG MATRIX
Phospholipase D1	Enzyme	Q13393	PLD1_HUMAN		IC50	5.40	CHEMBL
Phospholipase D2	Enzyme	O14939	PLD2_HUMAN		IC50	5.47	CHEMBL
Complement C5	Secreted	P01031	CO5_HUMAN		Kd	6.15	CHEMBL
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	6.32	DRUG MATRIX
HLA class I histocompatibility antigen, A-3 alpha chain	Unclassified	P04439	1A03_HUMAN		Kd	4.66	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.71	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	5.83	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	6.07	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	6.63	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	5.66	CHEMBL
Estrogen receptor	Transcription factor		ESR1_RAT		Ki	9.43	CHEMBL
Estrogen receptor beta	Transcription factor		ESR2_RAT		Ki	8.56	CHEMBL
C-8 sterol isomerase	Enzyme		ERG2_YEAST		Ki	7.18	CHEMBL
Cruzipain	Enzyme		CYSP_TRYCR		IC50	4.48	CHEMBL
Estrogen receptor	Transcription factor		ESR1_RAT ESR2_RAT		IC50	8.73	CHEMBL

External reference:

ID	Source
4024098	VUID
N0000022103	NUI
D02217	KEGG_DRUG
82640-04-8	SECONDARY_CAS_RN
4021080	VANDF
4024098	VANDF
C0244404	UMLSCUI
CHEBI:8772	CHEBI
RAL	PDB_CHEM_ID
CHEMBL81	ChEMBL_ID
CHEMBL1116	ChEMBL_ID
D020849	MESH_DESCRIPTOR_UI
DB00481	DRUGBANK_ID
2820	IUPHAR_LIGAND_ID
5388	INN_ID
YX9162EO3I	UNII
5035	PUBCHEM_CID
166551	RXNORM
11500	MMSL
5410	MMSL
83711	MMSL
d04261	MMSL
007282	NDDF
007283	NDDF
109029006	SNOMEDCT_US
395856004	SNOMEDCT_US
419530003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Evista	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4184	TABLET	60 mg	ORAL	NDA	33 sections
Evista	HUMAN PRESCRIPTION DRUG LABEL	1	0002-4184	TABLET	60 mg	ORAL	NDA	33 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7290	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0440-5295	TABLET, FILM COATED	60 mg	ORAL	ANDA	20 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6902	TABLET, FILM COATED	60 mg	ORAL	ANDA	30 sections
Raloxifene Hydrochloride	Human Prescription Drug Label	1	16714-213	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	31722-256	TABLET	60 mg	ORAL	ANDA	20 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42291-726	TABLET, FILM COATED	60 mg	ORAL	ANDA	31 sections
Raloxifene Hydrochloride	Human Prescription Drug Label	1	43353-253	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43598-505	TABLET, FILM COATED	60 mg	ORAL	ANDA	30 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3363	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-3866	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5458	TABLET	60 mg	ORAL	ANDA	27 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50228-306	TABLET, FILM COATED	60 mg	ORAL	ANDA	30 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50268-694	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Evista	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4170	TABLET	60 mg	ORAL	NDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	60687-266	TABLET	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-7708	TABLET	60 mg	ORAL	ANDA	27 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8209	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	65162-057	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	65162-057	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	Human Prescription Drug Label	1	65862-709	TABLET, FILM COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	Human Prescription Drug Label	1	66993-661	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68071-2412	TABLET, FILM COATED	60 mg	ORAL	ANDA	30 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	69097-825	TABLET	60 mg	ORAL	ANDA	28 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2994	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	70518-3046	TABLET	60 mg	ORAL	ANDA	28 sections
Raloxifene hydrochloride	Human Prescription Drug Label	1	71209-082	TABLET, COATED	60 mg	ORAL	ANDA	28 sections
Raloxifene hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	71335-1460	TABLET, FILM COATED	60 mg	ORAL	ANDA	29 sections
Raloxifene Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	71335-1663	TABLET	60 mg	ORAL	ANDA	27 sections